Business Wire

  1. Truvian Health Rapidly Expands TruVerus Menu With FDA Clearances For Cardiovascular, Liver, And Core Metabolic Health Tests 1/12/2026

    Truvian Health (“Truvian”), a transformational diagnostics company redefining healthcare, today announced it has received 510(k) clearances (K251091, K251074, K251157) from the U.S. Food and Drug Administration (FDA) for nine additional analytes for TruVerus, the industry’s first FDA cleared multimodal benchtop blood analyzer.

  2. Thermo Fisher Scientific Announces Strategic Collaboration With NVIDIA Leveraging AI To Advance Scientific Instrumentation And Accelerate Laboratory Performance 1/12/2026

    Thermo Fisher Scientific Inc. the world leader in serving science, announced a strategic collaboration with NVIDIA to power AI-based solutions and laboratory automation at scale.

  3. Alpenglow Biosciences And PathNet Form Strategic Partnership To Advance National Platform For 3D AI Cancer Diagnostics 1/8/2026

    Alpenglow Biosciences, the leader in clinical-grade 3D digital pathology and AI-powered spatial analytics, and PathNet, one of the nation’s foremost pathology laboratories and largest independent urologic oncology pathology networks, today announced a strategic partnership to develop, validate, and commercialize 3D AI-enabled diagnostic tests for prostate and bladder cancer.

  4. Prolytix Expands Capabilities In Thrombosis And Hemostasis Testing 1/8/2026

    Prolytix, a U.S.-based leader in bioanalytical and protein characterization services, announces it has acquired 60 validated assays previously owned by Hemostasis Reference Laboratory (HRL).

  5. Cardio Diagnostics, Aimil Ltd. And Dr. Lal PathLabs Limited Partner To Launch The PrecisionCHD Test In India 1/7/2026

    Cardio Diagnostics Holdings, Inc. a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India’s most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories and 300+ MD pathologists in their internal network, today announced a strategic agreement to launch Cardio Diagnostics’ PrecisionCHD test for the detection and management of coronary heart disease (CHD) in India.

  6. PracticeQ Partners With Fullscript To Streamline Lab Testing And Improve Patient Care 1/6/2026

    PracticeQ today announced the launch of its new labs on Fullscript integration, designed to give providers a seamless way to order, track, and manage lab testing directly within their clinical workflows.

  7. Valar Labs Announces Strategic Partnership With PathNet Lab To Deliver AI-Driven Bladder Cancer Insights Nationwide 12/22/2025

    Valar Labs, a leader in AI-powered diagnostics for oncology, today announced a strategic partnership with PathNet Lab, one of the nation’s foremost pathology laboratories.

  8. Fulgent Genetics Agrees To Acquire Bako Diagnostics And StrataDx 12/22/2025

    Fulgent Genetics, Inc. (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics (“Bako”), a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, MA.

  9. CellTivity Scientific Receives CE Registration For The Van Gogh Microscopy System, Enabling Real Time Diagnostic Sampling Support Across Europe 12/17/2025

    CellTivity Scientific, a leader in point of care disease detection, today announced that the Van Gogh Microscopy System has received CE registration, enabling clinical use and commercial distribution across the European Union.

  10. Cofactor Genomics Announces Strategic Investment By Labcorp And Ascension Ventures To Fuel Expansion Of Its OncoPrism Immunotherapy Diagnostic Across U.S. Cancer Care Networks 12/15/2025

    Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures.